Meeting Highlights: Global Regulatory Sessions

The Evolving International Landscape of FDA Inspections: Data Integrity Violations in Bioequivalence Studies in India

Panelists will use a case-study format and present the risk-based approach used to select sites for inspection and discuss the role of FDA’s international offices in facilitating inspections and engaging with regulatory counterparts in country.

Update from the CFDA

This session will provide an overview of CFDA regulatory reform and an update on key important initiatives.

Update from CBER: Advancing the Development of Complex Biologic Products

Panelists will provide an overview of how the Center for Biologics Evaluation and Research (CBER) works to advance the development of biological products such as vaccines, live biotherapeutics, and cellular and gene therapies.

Recent Trends in Asian Regulations for Drug Development: What is Coming Next?

Regulatory agencies from major East Asian countries including Japan, Singapore, and Taiwan, together with the industry representation, will give an overview of the recent regulatory environment changes in each country.

International Collaboration in Times of Public Health Crisis

Learn how regulators have and are demonstrating a willingness to find new and pragmatic ways of working together with industry with the ultimate goal of providing health care solutions which are in high-demand by society.

PMDA Town Hall

PMDA’s executive staff will discuss progress made towards achieving the goals outlined in its “PMDA International Strategic Plan 2015”, as well as other initiatives currently underway and new initiatives to further PMDA’s contributions to global health.

Brexit: Where Are We Now?

Gain an overview of the current state of play of the political process from a UK as well as an EU perspective.

International Regulatory Convergence

Join senior leadership from international regulatory authorities to hear the latest on multi- and bilateral initiatives that avoid duplication and increase mutual reliance, their strategic governance, and their impact on industry.

Global Perspective on ICH: Part 1 of 2

A panel of experts will discuss the benefits of ICH and global regulatory harmonization, including views on key strategic topics that will enhance simultaneous global drug development.

FDA – Health Canada Regulatory Cooperation Council Town Hall

FDA and Health Canada will highlight their work under RCC Phase 2 and request stakeholder input on their current initiatives.

Global Perspective on ICH: Part 2 of 2

The expert panel will continue the discussion on the benefits of ICH and global regulatory harmonization, including views on key strategic topics that will enhance simultaneous global drug development.

EMA/FDA Question Time

EMA and FDA leadership will engage in a round table discussion on areas covered by the EMA/FDA confidentiality arrangements and discuss how both agencies contribute to global development and supervision of medicines.

Registration Rates

Back to DIA 2017

Back to DIAglobal.org